ECOR — electroCore, Inc.

Summary of electroCore Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 2025 revenue reached $8.7 million, a 33% increase year-over-year and an 18% increase sequentially.
• Gross Margin: Maintained at 86%, slightly up from 84% in Q3 2024.
• Prescription Device Revenue: Grew 19% year-over-year to $6.8 million, driven by sales in the VA hospital system.
• Health and Wellness Product Revenue: Increased 54% sequentially and 121% year-over-year to $1.9 million.
• Net Loss: Reported at $3.4 million or $0.40 per share, compared to a loss of $2.5 million or $0.31 per share in Q3 2024.
• Adjusted EBITDA: Loss narrowed to $2 million from $2.1 million in the prior year.
• Cash Position: As of September 30, 2025, cash balance was $13.2 million, with a forecasted balance of $10.5 million by year-end.

2. Strategic Updates and Business Highlights

• Acquisition of NeuroMetrix: Closed on May 1, 2025, enhancing the product portfolio with the Quell Fibromyalgia device, which has exceeded revenue expectations.
• VA Channel Growth: Secured a new 5-year contract with the VA, expanding sales efforts and increasing the number of VA facilities purchasing electroCore products from 166 to 195.
• Truvaga Sales Growth: Returned to growth, driven by direct-to-consumer sales and partnerships with influencers and affiliates.
• Wellness Division Development: Partnered with StratejAI to develop AI-driven software for wellness products, targeting a growing market opportunity.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased full-year 2025 revenue guidance to $31.5 million to $32.5 million.
• Profitability Timeline: Expected to achieve cash-positive operations with adjusted EBITDA at approximately $12 million in quarterly revenue, targeted for the second half of 2026.
• Investment Strategy: Continued investment in sales and marketing to support growth, with an anticipated increase in operating expenses.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The net loss widened due to higher operating expenses and acquisition-related costs.
• Regulatory and Competitive Risks: Ongoing litigation regarding patent infringement from a competitor (Pulsetto) could impact market position.
• Government Shutdown Impact: The current government shutdown has caused a slowdown in revenue generation, particularly affecting the TAC-STIM product line.
• Cash Burn Rate: Approximately $1.5 million used in Q3 2025, raising concerns about cash management as the company approaches its forecasted cash balance.

5. Notable Q&A Insights

• Quell Fibromyalgia Adoption: Strong uptake in the VA market attributed to the safety profile and unmet clinical needs in fibromyalgia treatment.
• Future Sales Strategy: Plans to replicate success in the VA channel to other managed care systems, with cautious expansion.
• Next-Gen Mobile App: Development is focused on Truvaga Plus initially, with plans to harmonize apps for different products in the future.
• China Market Potential: A partnership with a significant investor to commercialize products in China, with no direct capital investment from electroCore, but potential royalties from sales.

Overall, electroCore is navigating a pivotal growth phase with strategic investments and acquisitions aimed at long-term value creation, despite facing challenges related to profitability and competitive pressures.